Folic Acid, Vit B9 / ROS Cancer Research Results

FA, Folic Acid, Vit B9: Click to Expand ⟱
Features:
B Vitamin supplement. Helps form red blood cells.
Folic acid (vitamin B9) is converted into tetrahydrofolate (THF) and its derivatives. These folate coenzymes are essential for one‐carbon transfer reactions, which are critical for the synthesis of purines and thymidylate—key components of DNA.

• Folate Deficiency and ROS: A deficiency in folic acid can exacerbate oxidative stress. Insufficient folate has been linked to increased ROS levels, which are capable of damaging cellular macromolecules, including DNA, proteins, and lipids. This oxidative DNA damage further increases mutation rates and contributes to carcinogenesis.

The evidence suggests that while adequate dietary folate is important for cancer prevention (by maintaining genomic stability and proper methylation), excessive folate supplementation in individuals with undiagnosed or existing neoplasms might be problematic.

-supplementation of folate may occur as folic acid, folinic acid or 5-methyltetrahydrofolate (5-MTHF).
-5-MTHF also known as L-methylfolate
-Naturally occurring 5-MTHF has important advantages over synthetic folic acid - it is well absorbed even when gastrointestinal pH is altered and its bioavailability is not affected by metabolic defects
-Use of 5-MTHF also prevents the potential negative effects of unconverted folic acid in the peripheral circulation
-Large RCT meta-analyses generally do not show a moderate increase in overall cancer incidence from folic acid during trial periods.
-High-dose folic acid has a long-running concern about “timing” (before vs after neoplasia), and NIH ODS cautions against >1,000 µg/day from supplements (UL) largely due to masking B12 deficiency and risk-uncertainty contexts.

-It’s best categorized as a “growth substrate / one-carbon cofactor” with high chemo-interaction relevance, not as a standalone anticancer natural product.

Rank Pathway / Axis Cancer / Tumor Context Normal Tissue Context TSF Primary Effect Notes / Interpretation
1 One-carbon metabolism → nucleotide synthesis (dTMP & purines) DNA/RNA synthesis capacity ↑ (supports proliferation if limiting) Essential for normal cell replication/repair R, G Replication substrate support Folate carries one-carbon units used for thymidylate and purine synthesis (core reason antifolates exist in oncology).
2 Methylation capacity (methionine cycle coupling: SAM/SAH balance) Epigenetic tone can shift (context-dependent) Supports normal methylation/homeostasis G Epigenetic/biochemical regulation Folate status influences methyl donor availability; effects can differ by tumor type and baseline folate state.
3 Homocysteine remethylation (folate-B12 axis) Indirect; not a primary tumor pathway Homocysteine ↓ when deficient state corrected G Systemic metabolic effect Clinically important for deficiency correction; not a direct anticancer mechanism.
4 Interaction with antifolate chemotherapy (methotrexate class) Can counter antifolate effect depending on form/timing Used to reduce toxicity in specific regimens (folinic acid/leucovorin rescue) R Chemo interaction (high-impact) Folinic acid (leucovorin) is used as “rescue” after high-dose methotrexate to mitigate toxicity; this is regimen-specific.
5 5-FU modulation via reduced folate pool (leucovorin synergy) Can enhance 5-FU thymidylate synthase inhibition (when folinic acid used) Also increases toxicity risk (regimen-dependent) R Chemo potentiation (protocol-defined) Leucovorin (folinic acid) is used clinically to enhance 5-FU efficacy by stabilizing TS inhibition; this is not “general folic acid supplementation.” :contentReference[oaicite:2]{index=2}
6 Cancer risk signal (supplement timing/dose debates) Overall RCT meta-analyses: no moderate overall increase during trials Translation constraint Large meta-analyses of RCTs generally do not show a moderate increase in overall cancer incidence from folic acid supplementation during trial periods; timing and subgroup questions remain debated. :contentReference[oaicite:3]{index=3}
7 Upper intake constraint (supplemental folic acid) High-dose use should be cautious without indication UL for folic acid from supplements/fortified foods: 1,000 µg/day (adults) Safety/monitoring NIH ODS notes the adult UL is 1,000 µg/day for folic acid; excess can mask B12 deficiency and may be undesirable in some contexts. :contentReference[oaicite:4]{index=4}
8 Bioavailability / form distinction (folate vs folic acid vs folinic acid) Form matters for chemo interactions and interpretation Form matters for deficiency correction P, R Interpretation constraint “Folate” (food forms), “folic acid” (synthetic), and “folinic acid/leucovorin” (reduced folate used in oncology protocols) are not interchangeable clinically.

Time-Scale Flag (TSF): P / R / G

  • P: 0–30 min (absorption/early availability; limited “instant” pathway effects)
  • R: 30 min–3 hr (acute pool shifts; relevant mainly in drug-modulation contexts)
  • G: >3 hr (methylation/nucleotide supply effects; phenotype-level outcomes)


Chemo Interaction Mini-Table
Drug / Regimen Folate-Related Agent Interaction Type Mechanism (What’s happening) Clinical Use / Practical Note Net Effect
High-dose Methotrexate (HD-MTX) Leucovorin (folinic acid; calcium folinate) Rescue (toxicity mitigation) Provides reduced folate to “rescue” normal cells from MTX-induced reduced-folate depletion; not given simultaneously because it can blunt MTX effect. Standard component of HD-MTX supportive care (timing is protocol-defined; typically starts after MTX). ↓ toxicity while preserving efficacy when timed correctly :contentReference[oaicite:0]{index=0}
5-Fluorouracil (5-FU) regimens
(e.g., colorectal protocols)
Leucovorin (folinic acid) Potentiation (efficacy enhancement) Increases and stabilizes thymidylate synthase (TS) inhibition by promoting formation of the inhibitory ternary complex (5-FU metabolite + TS + reduced folate cofactor). Intentional synergy; also increases risk of GI and marrow toxicity vs 5-FU alone (protocol-dependent). ↑ efficacy + often ↑ toxicity :contentReference[oaicite:1]{index=1}
Pemetrexed (antifolate chemotherapy) Folic acid (oral) + Vitamin B12 (IM) Required supplementation (toxicity reduction) Supplementation reduces severity of hematologic and GI toxicity during pemetrexed therapy. Start before first dose, continue during treatment, and continue after last dose per label/protocol. ↓ toxicity (standard of care) :contentReference[oaicite:2]{index=2}
“Folic acid” vs “Leucovorin”
(naming pitfall)
Folic acid (synthetic) vs Leucovorin (reduced folate) Non-interchangeable Leucovorin is a reduced folate used for MTX rescue and 5-FU potentiation; folic acid is mainly a nutritional supplement and not a direct substitute in these oncology protocols. Use the specific agent indicated by protocol; don’t swap terms in notes. Interpretation / protocol-critical :contentReference[oaicite:3]{index=3}
General supplementation safety note High-dose folic acid supplements Monitoring issue Large folate intakes can mask hematologic signs of B12 deficiency while neurologic injury progresses. Relevant when documenting “high-dose folate” use outside oncology protocols. Safety constraint :contentReference[oaicite:4]{index=4}


ROS, Reactive Oxygen Species: Click to Expand ⟱
Source: HalifaxProj (inhibit)
Type:
Reactive oxygen species (ROS) are highly reactive molecules that contain oxygen and can lead to oxidative stress in cells. They play a dual role in cancer biology, acting as both promoters and suppressors of cancer.
ROS can cause oxidative damage to DNA, leading to mutations that may contribute to cancer initiation and progression. So normally you want to inhibit ROS to prevent cell mutations.
However excessive ROS can induce apoptosis (programmed cell death) in cancer cells, potentially limiting tumor growth. Chemotherapy typically raises ROS.
-mitochondria is the main source of reactive oxygen species (ROS) (and the ETC is heavily related)

"Reactive oxygen species (ROS) are two electron reduction products of oxygen, including superoxide anion, hydrogen peroxide, hydroxyl radical, lipid peroxides, protein peroxides and peroxides formed in nucleic acids 1. They are maintained in a dynamic balance by a series of reduction-oxidation (redox) reactions in biological systems and act as signaling molecules to drive cellular regulatory pathways."
"During different stages of cancer formation, abnormal ROS levels play paradoxical roles in cell growth and death 8. A physiological concentration of ROS that maintained in equilibrium is necessary for normal cell survival. Ectopic ROS accumulation promotes cell proliferation and consequently induces malignant transformation of normal cells by initiating pathological conversion of physiological signaling networks. Excessive ROS levels lead to cell death by damaging cellular components, including proteins, lipid bilayers, and chromosomes. Therefore, both scavenging abnormally elevated ROS to prevent early neoplasia and facilitating ROS production to specifically kill cancer cells are promising anticancer therapeutic strategies, in spite of their contradictoriness and complexity."
"ROS are the collection of derivatives of molecular oxygen that occur in biology, which can be categorized into two types, free radicals and non-radical species. The non-radical species are hydrogen peroxide (H 2O 2 ), organic hydroperoxides (ROOH), singlet molecular oxygen ( 1 O 2 ), electronically excited carbonyl, ozone (O3 ), hypochlorous acid (HOCl, and hypobromous acid HOBr). Free radical species are super-oxide anion radical (O 2•−), hydroxyl radical (•OH), peroxyl radical (ROO•) and alkoxyl radical (RO•) [130]. Any imbalance of ROS can lead to adverse effects. H2 O 2 and O 2 •− are the main redox signalling agents. The cellular concentration of H2 O 2 is about 10−8 M, which is almost a thousand times more than that of O2 •−".
"Radicals are molecules with an odd number of electrons in the outer shell [393,394]. A pair of radicals can be formed by breaking a chemical bond or electron transfer between two molecules."

Recent investigations have documented that polyphenols with good antioxidant activity may exhibit pro-oxidant activity in the presence of copper ions, which can induce apoptosis in various cancer cell lines but not in normal cells. "We have shown that such cell growth inhibition by polyphenols in cancer cells is reversed by copper-specific sequestering agent neocuproine to a significant extent whereas iron and zinc chelators are relatively ineffective, thus confirming the role of endogenous copper in the cytotoxic action of polyphenols against cancer cells. Therefore, this mechanism of mobilization of endogenous copper." > Ions could be one of the important mechanisms for the cytotoxic action of plant polyphenols against cancer cells and is possibly a common mechanism for all plant polyphenols. In fact, similar results obtained with four different polyphenolic compounds in this study, namely apigenin, luteolin, EGCG, and resveratrol, strengthen this idea.
Interestingly, the normal breast epithelial MCF10A cells have earlier been shown to possess no detectable copper as opposed to breast cancer cells [24], which may explain their resistance to polyphenols apigenin- and luteolin-induced growth inhibition as observed here (Fig. 1). We have earlier proposed [25] that this preferential cytotoxicity of plant polyphenols toward cancer cells is explained by the observation made several years earlier, which showed that copper levels in cancer cells are significantly elevated in various malignancies. Thus, because of higher intracellular copper levels in cancer cells, it may be predicted that the cytotoxic concentrations of polyphenols required would be lower in these cells as compared to normal cells."

Majority of ROS are produced as a by-product of oxidative phosphorylation, high levels of ROS are detected in almost all cancers.
-It is well established that during ER stress, cytosolic calcium released from the ER is taken up by the mitochondrion to stimulate ROS overgeneration and the release of cytochrome c, both of which lead to apoptosis.

Note: Products that may raise ROS can be found using this database, by:
Filtering on the target of ROS, and selecting the Effect Direction of ↑

Targets to raise ROS (to kill cancer cells):
• NADPH oxidases (NOX): NOX enzymes are involved in the production of ROS.
    -Targeting NOX enzymes can increase ROS levels and induce cancer cell death.
    -eNOX2 inhibition leads to a high NADH/NAD⁺ ratio which can lead to increased ROS
• Mitochondrial complex I: Inhibiting can increase ROS production
• P53: Activating p53 can increase ROS levels(by inducing the expression of pro-oxidant genes)
Nrf2 inhibition: regulates the expression of antioxidant genes. Inhibiting Nrf2 can increase ROS levels
• Glutathione (GSH): an antioxidant. Depleting GSH can increase ROS levels
• Catalase: Catalase converts H2O2 into H2O+O. Inhibiting catalase can increase ROS levels
• SOD1: converts superoxide into hydrogen peroxide. Inhibiting SOD1 can increase ROS levels
• PI3K/AKT pathway: regulates cell survival and metabolism. Inhibiting can increase ROS levels
HIF-1α inhibition: regulates genes involved in metabolism and angiogenesis. Inhibiting HIF-1α can increase ROS
• Glycolysis: Inhibiting glycolysis can increase ROS levels • Fatty acid oxidation: Cancer cells often rely on fatty acid oxidation for energy production.
-Inhibiting fatty acid oxidation can increase ROS levels
• ER stress: Endoplasmic reticulum (ER) stress can increase ROS levels
• Autophagy: process by which cells recycle damaged organelles and proteins.
-Inhibiting autophagy can increase ROS levels and induce cancer cell death.
• KEAP1/Nrf2 pathway: regulates the expression of antioxidant genes.
    -Inhibiting KEAP1 or activating Nrf2 can increase ROS levels and induce cancer cell death.
• DJ-1: regulates the expression of antioxidant genes. Inhibiting DJ-1 can increase ROS levels
• PARK2: regulates the expression of antioxidant genes. Inhibiting PARK2 can increase ROS levels
SIRT1 inhibition:regulates the expression of antioxidant genes. Inhibiting SIRT1 can increase ROS levels
AMPK activation: regulates energy metabolism and can increase ROS levels when activated.
mTOR inhibition: regulates cell growth and metabolism. Inhibiting mTOR can increase ROS levels
HSP90 inhibition: regulates protein folding and can increase ROS levels when inhibited.
• Proteasome: degrades damaged proteins. Inhibiting the proteasome can increase ROS levels
Lipid peroxidation: a process by which lipids are oxidized, leading to the production of ROS.
    -Increasing lipid peroxidation can increase ROS levels
• Ferroptosis: form of cell death that is regulated by iron and lipid peroxidation.
    -Increasing ferroptosis can increase ROS levels
• Mitochondrial permeability transition pore (mPTP): regulates mitochondrial permeability.
    -Opening the mPTP can increase ROS levels
• BCL-2 family proteins: regulate apoptosis and can increase ROS levels when inhibited.
• Caspase-independent cell death: a form of cell death that is regulated by ROS.
    -Increasing caspase-independent cell death can increase ROS levels
• DNA damage response: regulates the repair of DNA damage. Increasing DNA damage can increase ROS
• Epigenetic regulation: process by which gene expression is regulated.
    -Increasing epigenetic regulation can increase ROS levels

-PKM2, but not PKM1, can be inhibited by direct oxidation of cysteine 358 as an adaptive response to increased intracellular reactive oxygen species (ROS)

ProOxidant Strategy:(inhibit the Mevalonate Pathway (likely will also inhibit GPx)
-HydroxyCitrate (HCA) found as supplement online and typically used in a dose of about 1.5g/day or more
-Atorvastatin typically 40-80mg/day, -Dipyridamole typically 200mg 2x/day Combined effect research
-Lycopene typically 100mg/day range (note debatable as it mainly lowers NRF2)

Dual Role of Reactive Oxygen Species and their Application in Cancer Therapy
ROS-Inducing Interventions in Cancer — Canonical + Mechanistic Reference
-generated from AI and Cancer database
ROS rating:  +++ strong | ++ moderate | + weak | ± mixed | 0 none
NRF2:        ↓ suppressed | ↑ activated | ± mixed | 0 none
Conditions:  [D] dose  [Fe] metal  [M] metabolic  [O₂] oxygen
             [L] light [F] formulation [T] tumor-type [C] combination

Item ROS NRF2 Condition Mechanism Class Remarks
ROS">Piperlongumine +++ [D][T] ROS-dominant
ROS">Shikonin +++↓/±[D][T]ROS-dominant
ROS">Vitamin K3 (menadione) +++[D]ROS-dominant
ROS">Copper (ionic / nano) +++[Fe][F]ROS-dominant
ROS">Sodium Selenite +++[D]ROS-dominant
ROS">Juglone +++[D]ROS-dominant
ROS">Auranofin +++[D]ROS-dominant
ROS">Photodynamic Therapy (PDT) +++0[L][O₂]ROS-dominant
ROS">Radiotherapy / Radiation +++0[O₂]ROS-dominant
ROS">Doxorubicin +++[D]ROS-dominant
ROS">Cisplatin ++[D][T]ROS-dominant
ROS">Salinomycin ++[D][T]ROS-dominant
ROS">Artemisinin / DHA ++[Fe][T]ROS-dominant
ROS">Sulfasalazine ++[C][T]ROS-dominant
ROS">FMD / fasting ++[M][C][O₂]ROS-dominant
ROS">Vitamin C (pharmacologic) ++[Fe][D]ROS-dominant
ROS">Silver nanoparticles ++±[F][D]ROS-dominant
ROS">Gambogic acid ++[D][T]ROS-dominant
ROS">Parthenolide ++[D][T]ROS-dominant
ROS">Plumbagin ++[D]ROS-dominant
ROS">Allicin ++[D]ROS-dominant
ROS">Ashwagandha (Withaferin A) ++[D][T]ROS-dominant
ROS">Berberine ++[D][M]ROS-dominant
ROS">PEITC ++[D][C]ROS-dominant
ROS">Methionine restriction +[M][C][T]ROS-secondary
ROS">DCA +±[M][T]ROS-secondary
ROS">Capsaicin +±[D][T]ROS-secondary
ROS">Galloflavin +0[D]ROS-secondary
ROS">Piperine +±[D][F]ROS-secondary
ROS">Propyl gallate +[D]ROS-secondary
ROS">Scoulerine +?[D][T]ROS-secondary
ROS">Thymoquinone ±±[D][T]Dual redox
ROS">Emodin ±±[D][T]Dual redox
ROS">Alpha-lipoic acid (ALA) ±[D][M]NRF2-dominant
ROS">Curcumin ±↑/↓[D][F]NRF2-dominant
ROS">EGCG ±↑/↓[D][O₂]NRF2-dominant
ROS">Quercetin ±↑/↓[D][Fe]NRF2-dominant
ROS">Resveratrol ±[D][M]NRF2-dominant
ROS">Sulforaphane ±↑↑[D]NRF2-dominant
ROS">Lycopene 0Antioxidant
ROS">Rosmarinic acid 0Antioxidant
ROS">Citrate 00Neutral


Scientific Papers found: Click to Expand⟱
4071- FA,    Folate and Alzheimer: when time matters
- Review, AD, NA
*cognitive↑, *ROS↓, *Ca+2↓, *p‑tau↓, *Aβ↓,
4037- VitB12,  FA,    Mechanistic Link between Vitamin B12 and Alzheimer’s Disease
- Review, AD, NA
*antiOx↑, *ROS↓, *GSH↑, *Inflam↓, *IL6↓, *TNF-α↓, *other↑, *other↑, *other↑, *Aβ↓, *memory↑, *p‑tau↓, *APP↓, *BACE↓, *ATP↑, *neuroP↑,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Total Targets: 0

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress

antiOx↑, 1,   GSH↑, 1,   ROS↓, 2,  

Mitochondria & Bioenergetics

ATP↑, 1,  

Transcription & Epigenetics

other↑, 3,  

Migration

APP↓, 1,   Ca+2↓, 1,  

Immune & Inflammatory Signaling

IL6↓, 1,   Inflam↓, 1,   TNF-α↓, 1,  

Synaptic & Neurotransmission

p‑tau↓, 2,  

Protein Aggregation

Aβ↓, 2,   BACE↓, 1,  

Clinical Biomarkers

IL6↓, 1,  

Functional Outcomes

cognitive↑, 1,   memory↑, 1,   neuroP↑, 1,  
Total Targets: 17

Scientific Paper Hit Count for: ROS, Reactive Oxygen Species
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:80  Target#:275  State#:%  Dir#:1
wNotes=0 sortOrder:rid,rpid

 

Home Page